Sysmex (OTCMKTS:SSMXY) Updates FY 2025 Earnings Guidance

Sysmex (OTCMKTS:SSMXY - Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.430-0.430 for the period. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.3 billion.Sysmex Stock Down 9.6%Shares of OTCMKTS SSMXY traded down $0.90 during trading on Friday, reaching $8.52. The company had a trading volume of 132,855 shares, compared to its average volume of 270,785. Sysmex has a 12-month low of $8.15 and a 12-month high of $19.85. The company has a quick ratio of 2.49, a current ratio of 3.34 and a debt-to-equity ratio of 0.11. The business's 50-day moving average is $9.74 and its 200 day moving average is $11.39. The stock has a market cap of $5.36 billion, a PE ratio of 17.04 and a beta of 1.14. Sysmex (OTCMKTS:SSMXY - Get Free Report) last issued its earnings results on Thursday, February 12th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. The firm had revenue of $837.32 million for the quarter, compared to the consensus estimate of $819.99 million. Sysmex had a net margin of 9.32% and a return on equity of 9.86%. As a group, equities analysts forecast that Sysmex will post 0.57 earnings per share for the current fiscal year. Sysmex Company Profile (Get Free Report)Sysmex Corporation OTCMKTS: SSMXY is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex's product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics. The company's core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.Featured ArticlesFive stocks we like better than SysmexYour Bank Account Is No Longer SafeNvidia CEO Issues Bold Tesla CallBuy this Gold Stock Before May 2026What a Former CIA Agent Knows About the Coming CollapseNew gold price targetThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Sysmex Right Now?Before you consider Sysmex, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.While Sysmex currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here